BeOne plots accelerated approval for rare lymphoma drug after toplining Phase 1/2 data

BeOne Medicines said its candidate for a rare but aggressive form of B cell lymphoma has passed an early-stage test. Its BCL2 inhibitor, known as sonrotoclax, met the primary endpoint of overall response rate in ...